The present invention relates to cell culture media comprising alpha keto acids. The poor solubility of some amino acids like isoleucine, leucine and valine can be overcome by substituting them with the respective alpha keto acid.

The present disclosure relates to precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and a preparation method therefor. The precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells of the present disclosure have enhanced functionality and excellent proliferative capacity compared with typical mesenchymal stem cells or induced pluripotent stem cell-derived mesenchymal stem cells.

The present invention contemplates compositions, devices and methods of simulating biological fluids in a fluidic device, including but not limited to a microfluidic chip. In one embodiment, fluid comprising a colloid under flow in a microfluidic chip has a fluid density or viscosity similar to a bodily fluid, e.g. blood, lymph, lung fluid, or the like. In one embodiment, a fluid is provided as a Theologically biomimetic blood surrogate or substitute for simulating physiological shear stress and cell dynamics in fluidic device, including but not limited to immune cells.

An in vitro microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient's enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue, e.g., diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes (PBLs) and marrow infiltrating lymphocytes (MILs), from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and genetic modifications of expanded TILs, PBLs, and MILs to incorporate chimeric antigen receptors, genetically modified T-cell receptors, and other genetic modifications, and uses of such expanded and/or modified TILs, PBLs, and MILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

The present invention falls within the technical field of cell repair, and specifically relates to a method for repairing stem cells and a use thereof. On the basis of the original invention technology, following improvement, in the present invention, pulse wave-treated water having the function of repairing stem cells is obtained by means of pulse wave-treated water having pulse wave sequences with equal widths and unequal intervals, and the method has additive effects on multiple treated samples. Without influencing cell proliferation, a culture system prepared from the pulse wave-treated water can not only reduce the natural apoptosis effect of human umbilical cord mesenchymal stem cells (H-MSC), but also can inhibit injury-induced H-MSC apoptosis, and has a cell repair effect.

The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.

There is described an isolated 3-dimensional liver spheroid wherein said spheroid has: increased ATP content as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; the same or increased activity of cytochrome P450 1A1 and cytochrome P450 1B1 as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; and increased albumin secretion as compared to a 3-dimensional liver spheroid cultured in William's E medium alone.

A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. Colorectal cancer solid tumor tissues are treated with mild cell dissociation reagents, and colorectal cancer cells are isolated from ascites with a mild method, thereby ensuring the vitality of cancer cells to the greatest extent. A special serum-free medium is prepared, and colorectal cancer solid tumor-derived tumor cells are cultured in vitro with a suspension culture system to ensure normal expansion of the cancer cells while eliminating the interference of normal cells to the greatest extent. The colorectal cancer primary cell culture obtained by the method are usable for in vitro experiments, second-generation sequencing, building of animal models, and building of cell lines at multiple cell levels.

The invention relates to a new method for in vitro expansion of CD4+CD25.sup.HighCD127−.sup./LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.